Adam Silverman
Red Tree Venture Labs — Biologics at Red Tree Venture
About
Adam Silverman has nearly two decades of experience in the discovery and preclinical development of biotherapeutics. He began his industry career at Takeda working on antibody discovery and drug target identification in oncology, autoimmunity, and metabolic disorders, then joined Denali Therapeutics where he contributed to its blood-brain barrier Transport Vehicle platform and AVLAYAH, an enzyme replacement therapy for Hunter's Syndrome. He later led research teams at Codexis, advancing enzyme therapies for metabolic disorders, and at Spotlight Therapeutics, building a cell-targeted gene editing platform, and holds a B.S. from MIT and a Ph.D. in chemistry from Stanford University.
Invests in
Biotech
Colleagues at Red Tree Venture
Antonio Lepore
Senior Associate at Red Tree Venture
Ariell Ortega
Executive Assistant at Red Tree Venture
Bill Robinson
Scientific Advisory Board - Immunology; Chief, Stanford Division of Immunology and Rheumatology at Red Tree Venture
Brian Stearns
Red Tree Venture Labs Chemistry at Red Tree Venture
Cassie Lue
VP of Investor Relations at Red Tree Venture
Crystal Mackall
Scientific Advisory Board - Oncology; Director, Stanford Center for Cancer Cell Therapy at Red Tree Venture
Deborah Nguyen
Red Tree Venture Labs Operating Partner at Red Tree Venture
Frank Longo
Scientific Advisory Board - Neuro; Former Chair, Stanford Dept. of Neurology and Neurological Sciences at Red Tree Venture